NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery

Nanomedicine

Volumn 4, Issue 8, 2009, Pages 903-917

  Nowacek, Ari S ^a   Miller, Reagan L ^b   McMillan, JoEllyn ^a   Kanmogne, Georgette ^a   Kanmogne, Michel ^a   Mosley, R Lee ^a   Ma, Zhiya ^a   Graham, Sabine ^b   Chaubal, Mahesh ^b   Werling, Jane ^b   Rabinow, Barrett ^b   Dou, Huanyu ^a   Gendelman, Howard E ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Antiretroviral therapy; Antiviral response; HIV; Monocyte derived macrophage; NanoART; Nanoparticle

Indexed keywords

EFAVIRENZ; INDINAVIR; NANOPARTICLE; RITONAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SYNTHESIS; DRUG UPTAKE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; MONOCYTE; NANOMEDICINE; PARTICLE SIZE; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; VIRION; ZETA POTENTIAL;

ANTI-HIV AGENTS; BENZOXAZINES; CELL SURVIVAL; CELLS, CULTURED; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MACROPHAGES; MICROSCOPY, ATOMIC FORCE; MONOCYTES; NANOPARTICLES; RITONAVIR;

EID: 73349132394     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.09.71     Document Type: Article

References (49)

1. Hawkins T: Appearance-related side effects of HIV-1 treatment. AIDS Patient Care STDS 20(1), 6-18 (2006).
2. Shehu-Xhilaga M, Tachedjian G, Crowe SM, Kedzierska K: Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1. Curr. Med. Chem. 12(15), 1705-1719 (2005).
3. Delaugerre C, Peytavin G, Dominguez S et al.: Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097). J. Med. Virol. 77(3), 345-350 (2005).
4. Duval X, Peytavin G, Albert I et al.: Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients. HIV Med. 5(4), 307-313 (2004).
5. Hammer SM, Eron JJ Jr, Reiss P et al.: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300(5), 555-570 (2008).
6. Epstein LG, Gendelman HE: Human immunodeficiency virus type 1 infection of the nervous system: pathogenetic mechanisms. Ann. Neurol. 33(5), 429-436 (1993).
7. Best BM, Letendre SL, Brigid E et al.: Low atazanavir concentrations in cerebrospinal fluid. AIDS 23(1), 83-87 (2009).
8. Pathan SA, Iqbal Z, Zaidi SM et al.: CNS drug delivery systems: novel approaches. Recent Pat. Drug Deliv. Formul. 3(1), 71-89 (2009).
9. Varatharajan L, Thomas SA: The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 82(2), A99-A109 (2009).
10. Murri R, Lepri AC, Cicconi P et al.: Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian cohort of antiretroviral-naive patients study. J. Acquir. Immune Defic. Syndr. 41(1), 23-30 (2006).
11. Alos L, Navarrete P, Morente V et al.: Immunoarchitecture of lymphoid tissue in HIV-infection during antiretroviral therapy correlates with viral persistence. Mod. Pathol. 18(1), 127-136 (2005).
12. Paterson DL, Swindells S, Mohr J et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133(1), 21-30 (2000).
13. Bruce RD, McCance-Katz E, Kharasch ED, Moody DE, Morse GD: Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin. Infect. Dis. 43(Suppl. 4), S216-S223 (2006).
14. Bruce RD, Altice FL, Gourevitch MN, Friedland GH: Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J. Acquir. Immune Defic. Syndr. 41(5), 563-572 (2006).
15. Chulamokha L, DeSimone JA, Pomerantz RJ: Antiretroviral therapy in the developing world. J. Neurovirol. 11(Suppl. 1), 76-80 (2005).
16. De Cock K, Grubb I: Towards universal access: WHO's role in HIV prevention, treatment and care. Bull. World Health Organ. 84(7), 506 (2006).
17. Dou H, Destache CJ, Morehead JR et al.: Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 108(8), 2827-2835 (2006).
18. Dou H, Morehead J, Destache CJ et al.: Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology 358(1), 148-158 (2007).
19. Gorantla S, Dou H, Boska M et al.: Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery. J. Leukoc. Biol. 80(5), 1165-1174 (2006).
20. Gendelman HE, Kabanov A, Linder J: The promise and perils of CNS drug delivery: a video debate. J. Neuroimmune Pharmacol. 3(2), 58 (2008).
21. Gendelman HE, Orenstein JM, Martin MA et al.: Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J. Exp. Med. 167(4), 1428-1441 (1988).
22. Kalter DC, Greenhouse JJ, Orenstein JM, Schnittman SM, Gendelman HE, Meltzer MS: Epidermal Langerhans cells are not principal reservoirs of virus in HIV disease. J. Immunol. 146(10), 3396-3404 (1991).
23. 3H]thymidine incorporation assay. J. Immunol. Methods 170(2), 211-224 (1994).
24. Chaudhuri A, Yang B, Gendelman HE, Persidsky Y, Kanmogne GD: STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier. Blood 111(4), 2062-2072 (2008).
25. Chaudhuri A, Duan F, Morsey B, Persidsky Y, Kanmogne GD: HIV-1 activates proinflammatory and interferon-inducible genes in human brain microvascular endothelial cells: putative mechanisms of blood-brain barrier dysfunction. J. Cereb. Blood Flow Metab. 28(4), 697-711 (2008).
26. Fellay J, Boubaker K, Ledergerber B et al.: Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 358(9290), 1322-1327 (2001).
27. Dou H, Grotepas CB, McMillan JM et al.: Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J. Immunol. 183(1), 661-669 (2009).
28. Swindells S, DiRienzo AG, Wilkin T et al.: Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 296(7), 806-814 (2006).
29. McKinnon JE, Mellors JW, Swindells S: Simplification strategies to reduce antiretroviral drug exposure: progress and prospects. Antivir. Ther. 14(1), 1-12 (2009).
30. Kabanov AV, Gendelman HE: Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog. Polym. Sci. 32, 1054-1082 (2007).
31. Kingsley JD, Dou H, Morehead J, Rabinow B, Gendelman HE, Destache CJ: Nanotechnology: a focus on nanoparticles as a drug delivery system. J. Neuroimmune Pharmacol. 1(3), 340-350 (2006).
32. Rabinow BE: Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3(9), 785-796 (2004).
33. Couvreur P, Stella B, Reddy LH et al.: Squalenoyl nanomedicines as potential therapeutics. Nano Lett. 6(11), 2544-2548 (2006).
34. Vinogradov SV, Kohli E, Zeman AD: Cross-linked polymeric nanogel formulations of 5'-triphosphates of nucleoside analogues: role of the cellular membrane in drug release. Mol. Pharm. 2(6), 449-461 (2005).
35. Kuo YC: Loading efficiency of stavudine on polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate copolymer nanoparticles. Int. J. Pharm. 290(1-2), 161-172 (2005).
36. Kuo YC, Chen HH: Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles. Int. J. Pharm. 365(1-2), 206-213 (2009).
37. Jain SK, Gupta Y, Jain A, Saxena AR, Khare P: Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery. Nanomedicine 4(1), 41-48 (2008).
38. Baert L, van 't Klooster G, Dries W et al.: Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur. J. Pharm. Biopharm. 72(3), 502-528 (2009).
39. Rainer MK: Risperidone long-acting injection: a review of its long term safety and efficacy. Neuropsychiatr. Dis. Treat. 4(5), 919-927 (2008).
40. Taylor DM, Fischetti C, Sparshatt A, Thomas A, Bishara D, Cornelius V: Risperidone long-acting injection: a prospective 3-year ana lysis of its use in clinical practice. J. Clin. Psychiatry 70(2), 196-200 (2009).
41. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K: Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am. J. Psychiatry 160(6), 1125-1132 (2003).
42. Altamura AC, Sassella F, Santini A, Montresor C, Fumagalli S, Mundo E: Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 63(5), 493-512 (2003).
43. Beduneau A, Ma Z, Grotepas CB et al.: Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles. PLoS ONE 4(2), e4343 (2009).
44. Vonarbourg A, Passirani C, Saulnier P, Simard P, Leroux JC, Benoit JP: Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. J. Biomed. Mater. Res. A 78(3), 620-628 (2006).
45. Tabata Y, Ikada Y: Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials 9(4), 356-362 (1988).
46. Mainardes RM, Gremiao MP, Brunetti IL, da Fonseca LM, Khalil NM: Zidovudine-loaded PLA and PLA-PEG blend nanoparticles: influence of polymer type on phagocytic uptake by polymorphonuclear cells. J. Pharm. Sci. 98(1), 257-267 (2009).
47. Gaucher G, Asahina K, Wang J, Leroux JC: Effect of poly(N-vinyl- pyrrolidone)-blockpoly(D,L-lactide) as coating agent on the opsonization, phagocytosis, and pharmacokinetics of biodegradable nanoparticles. Biomacromolecules 10(2), 408-416 (2009).
48. Sant S, Poulin S, Hildgen P: Effect of polymer architecture on surface properties, plasma protein adsorption, and cellular interactions of pegylated nanoparticles. J. Biomed. Mater. Res. A 87(4), 885-895 (2008).
49. Roser M, Fischer D, Kissel T: Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur. J. Pharm. Biopharm. 46(3), 255-263 (1998).